Related Tags >> multiple sclerosis Tysabri FDA Elan

sclerosis drug News

Most Popular sclerosis drug Story

Sources: Biogen gets bidders, with Pfizer in lead

November 8, 2007 — 6:59am ET

The Financial Times is reporting some tantalizing details about the bidding for Biogen Idec, the biotech based in Cambridge, MA, that Read more...

sclerosis drug Press Releases

Driven by the Launch of Novel Disease-Modifying Therapies, the Multiple Sclerosis Drug Market Will Increase from $8.9 Bill
PROLOR To Present Long-Acting Obesity and Multiple Sclerosis Drug Candidates at Leading Neuropeptide Conference
CIGNA and EMD Serono Team to Fight Multiple Sclerosis Under First Outcomes-Based Specialty Medication Contract
Genzyme Confirms Receipt of Unsolicited Proposal
Aeolus Pharmaceuticals Announces Initiation of Multiple Dose Study of AEOL 10150 in a Patient with ALS

Latest Headlines

Lilly sees pipeline hope in MS drug
February 11, 2008
ALSO NOTED: Acorda shares bounce on new data; Endo CEO hits the exit door; BioSante in protocol deal; and much more...
January 29, 2008
Sources: Biogen gets bidders, with Pfizer in lead
November 8, 2007
Tysabri gets European backing at EMEA
April 27, 2006
Novartis M.S. drug shows sustained efficacy
April 5, 2006
FDA delays decision on Tysabri
March 21, 2006
Neurologists criticize Tysabri study
March 2, 2006
NEJM publishes positive 2-year Tysabri data
March 1, 2006
FDA allows limited trial of Tysabri
February 15, 2006
SPOTLIGHT: Novartis touts mid-stage results for MS drug
October 2, 2005
Schering: MS drug reduces onset by 50%
September 29, 2005
Biogen requests renewed marketing of Tysabri
September 26, 2005
FEATURE: New generation of biomarkers may reduce health risks
July 21, 2005
Serono drug draws FDA warning on heart risk
May 24, 2005

Paid Research Reports

More Research Reports >>